i think the difference between SVR among pts who are undetecable at 2-4 weeks versus 12 weeks is sufficient that you will likely see a measurable difference in SVR between the 2 groups. however, on the whole the data do not seem to stack up all that well compared with other direct acting antivirals as single agent on top of SOC. if someone thinks the compound can be complementary with another DAA agent then it may get partnered, but there are quite a few other compounds that are likely more attractive for partnering imo
Market Data 
Markets 
AI
